Targeting GD2 after allogeneic SCT: effector cell composition defines the optimal use of ch14.18 and the bispecific antibody construct NG-CU (GD2-CD3)

Arendt, A. -M.; Heubach, F.; Maier, C. P.; Giardino, S.; Jung, G.; Kowalewski, E.; Rabsteyn, A.; Amorelli, G.; Seitz, C.; Schlegel, P.; Handgretinger, R.; Lang, P.

dc.contributor.author	Arendt, Anne-Marie
dc.contributor.author	Heubach, Florian
dc.contributor.author	Maier, Claus-Philipp
dc.contributor.author	Jung, Gundram
dc.contributor.author	Kowalewski, E.
dc.contributor.author	Rabsteyn, Armin
dc.contributor.author	Amorelli, Germano
dc.contributor.author	Seitz, Christian
dc.contributor.author	Schlegel, Paul Martin
dc.contributor.author	Handgretinger, Rupert
dc.contributor.author	Lang, Peter
dc.date.accessioned	2024-04-18T08:19:00Z
dc.date.available	2024-04-18T08:19:00Z
dc.date.issued	2023
dc.identifier.issn	0340-7004
dc.identifier.uri	http://hdl.handle.net/10900/152876
dc.language.iso	en	en
dc.publisher	New York : Springer	de_DE
dc.relation.uri	http://dx.doi.org/10.1007/s00262-023-03536-x
dc.subject.ddc	610	de_DE
dc.subject.ddc	570	de_DE
dc.title	Targeting GD2 after allogeneic SCT: effector cell composition defines the optimal use of ch14.18 and the bispecific antibody construct NG-CU (GD2-CD3)	de_DE
dc.type	Article	de_DE
utue.quellen.id	20240124000000_01114
utue.publikation.seiten	3813-3824	de_DE
utue.personen.roh	Arendt, A. -M.
utue.personen.roh	Heubach, F.
utue.personen.roh	Maier, C. P.
utue.personen.roh	Giardino, S.
utue.personen.roh	Jung, G.
utue.personen.roh	Kowalewski, E.
utue.personen.roh	Rabsteyn, A.
utue.personen.roh	Amorelli, G.
utue.personen.roh	Seitz, C.
utue.personen.roh	Schlegel, P.
utue.personen.roh	Handgretinger, R.
utue.personen.roh	Lang, P.
dcterms.isPartOf.ZSTitelID	Cancer Immunology Immunotherapy	de_DE
dcterms.isPartOf.ZS-Issue	11	de_DE
dcterms.isPartOf.ZS-Volume	72	de_DE
utue.fakultaet	04 Medizinische Fakultät
utue.fakultaet	07 Mathematisch-Naturwissenschaftliche Fakultät
utue.fakultaet	Sonstige